Drug intelligence / Profile preview

ATLX-2847

Development stage: Preclinical
Lead developer: Alchemab Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Parenteral

Overview

ATLX-2847 is a preclinical-stage monoclonal antibody developed by Alchemab Therapeutics for the treatment of muscle atrophy. It functions as an enzyme inhibitor targeting 15-hydroxyprostaglandin dehydrogenase (PGDH), the primary enzyme responsible for the degradation of prostaglandin E2 (PGE2). PGE2 is a critical signaling molecule that promotes muscle stem cell function and tissue regeneration. By inhibiting PGDH, ATLX-2847 aims to increase local levels of PGE2, thereby supporting muscle repair and counteracting atrophy. Alchemab Therapeutics has targeted the second half of 2026 for an Investigational New Drug (IND) filing for this program.

Targets

HPGD (15-hydroxyprostaglandin dehydrogenase)

Beyond the preview

Go deeper on ATLX-2847.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATLX-2847.

Explore the full profile